Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

Table S1 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma

<p>Supplementary Table S1: Genomic and clinical characteristics of the study cohort.</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Ryan D. Chow (15109654) (author)
Diğer Yazarlar:	Tai Michaels (15122331) (author), Stefania Bellone (15122334) (author), Tobias M.P. Hartwich (15122337) (author), Elena Bonazzoli (15122340) (author), Akiko Iwasaki (15122343) (author), Eric Song (15122346) (author), Alessandro D. Santin (15122349) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Therapeutic Research and Development Immuno-oncology Gynecological Cancers Endometrial cancer Immunotherapy Translational Research
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Table S2 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Yazar:: Ryan D. Chow (15109654)
Baskı/Yayın Bilgisi: (2025)

Table S3 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Yazar:: Ryan D. Chow (15109654)
Baskı/Yayın Bilgisi: (2025)

Table S4 from Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti–PD-1 Immunotherapy in Endometrial Carcinoma
Yazar:: Ryan D. Chow (15109654)
Baskı/Yayın Bilgisi: (2025)

Supplemental Table 1 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Yazar:: Zannel Blanchard (16617018)
Baskı/Yayın Bilgisi: (2025)

Supplemental Table 2 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Yazar:: Zannel Blanchard (16617018)
Baskı/Yayın Bilgisi: (2025)

Supplemental Table 3 from Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha–Mutant Endometrial Cancer
Yazar:: Zannel Blanchard (16617018)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Figure 5 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure 1 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Supplemental Figure 2 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas
Yazar:: Niccolò G. Santin (22229756)
Baskı/Yayın Bilgisi: (2025)

Table 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Table 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.xlsx
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Image 1_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Table 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.docx
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Image 3_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Image 2_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Image 5_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.jpg
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Image 4_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Image 6_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tif
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Image 7_Mutation profile and molecular heterogeneity in mismatch repair deficient endometrial carcinoma.tiff
Yazar:: Yumeng Cai (5591276)
Baskı/Yayın Bilgisi: (2025)

Table 1_Evaluation of microsatellite instability patterns in mismatch repair deficiency: a retrospective analysis of 285 endometrial cancers.docx
Yazar:: Cheng Wang (102692)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 1 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
Yazar:: Shigehiro Yagishita (15088446)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 2 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
Yazar:: Shigehiro Yagishita (15088446)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 3 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
Yazar:: Shigehiro Yagishita (15088446)
Baskı/Yayın Bilgisi: (2025)

Supplementary Figure 4 from Antitumor Effect of Farletuzumab Ecteribulin in Molecular Subtypes of Endometrial Cancer Patient-Derived Xenograft Models
Yazar:: Shigehiro Yagishita (15088446)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table S4 from Evolution and Co-occurrence of PI3K Pathway Gene Mutations in Endometrial Carcinoma Molecular Subtypes at the Single-Cell Level
Yazar:: Arnaud Da Cruz Paula (17316230)
Baskı/Yayın Bilgisi: (2025)

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis
Yazar:: Yi Tang (55726)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)

Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Yazar:: Martina S.J. McDermott (15206951)
Baskı/Yayın Bilgisi: (2025)